Literature DB >> 10344220

Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23.

E N Subong1, M J Shue, J I Epstein, J V Briggman, P K Chan, A W Partin.   

Abstract

BACKGROUND: The nuclear protein B23, nucleophosmin, is an RNA-associated nucleolar phosphoprotein reported to be more abundant in malignant and growing cells than in normal nondividing cells. We examined the levels of B23 in fresh human prostate tissue and in five human prostate cancer cell lines with monoclonal antibodies (mAb) to nucleophosmin (alpha-B23) and to human prostate cancer nuclear matrix proteins (PRO:4-216).
METHODS: mAb PRO:4-216 and mAb alpha-B23 were used for protein level detection. Nuclear matrix proteins (NMPs) were prepared from prostate tumor and five human prostate cancer cell lines: LNCaP, TSU, DU145, PC-3, and PPC-1. The NMPs were run on one-dimensional and two-dimensional (2D) electrophoresis gels for Western blot analysis with the two mAbs. Histologic sections from paraffin-embedded normal and cancerous prostate tissue were stained immunohistochemically with both mAbs.
RESULTS: PRO:4-216 and B23 mAbs identified a 40-kD protein (pI approximately 5.0) by Western blot analysis in the human prostate cancer cell lines and on two-dimensional blots of human prostate cancer NMPs. Immunohistochemical staining demonstrated large punctate nuclear dots in most cancer nuclei, while staining of normal tissue was less intense or absent. Predominant reactivity was of epithelial nuclei, with some minor reactivity of stromal nuclei. Red blood cells (RBCs) and white blood cells (WBCs) were routinely negative.
CONCLUSIONS: PRO:4-216, previously characterized as recognizing prostate cancer nuclear matrix proteins, recognized B23/nucleophosmin. PRO:4-216 and alpha-B23 showed intense immunohistochemical staining of B23/nucleophosmin in cancer nuclei compared to adjacent normal cells in paraffin-embedded prostate tissue. This preliminary study showed the potential of B23 as a tumor marker for human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10344220     DOI: 10.1002/(sici)1097-0045(19990601)39:4<298::aid-pros11>3.0.co;2-m

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  41 in total

1.  Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability.

Authors:  June Li; Daniel P Sejas; Sandeep Burma; David J Chen; Qishen Pang
Journal:  Carcinogenesis       Date:  2007-02-02       Impact factor: 4.944

Review 2.  Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.

Authors:  Rachel Rau; Patrick Brown
Journal:  Hematol Oncol       Date:  2009-12       Impact factor: 5.271

3.  mTOR transcriptionally and post-transcriptionally regulates Npm1 gene expression to contribute to enhanced proliferation in cells with Pten inactivation.

Authors:  Rafik Boudra; Rosyne Lagrafeuille; Corinne Lours-Calet; Cyrille de Joussineau; Gaëlle Loubeau-Legros; Cédric Chaveroux; Jean-Paul Saru; Silvère Baron; Laurent Morel; Claude Beaudoin
Journal:  Cell Cycle       Date:  2016-05-18       Impact factor: 4.534

4.  Human Adenovirus Core Protein V Is Targeted by the Host SUMOylation Machinery To Limit Essential Viral Functions.

Authors:  Nora Freudenberger; Tina Meyer; Peter Groitl; Thomas Dobner; Sabrina Schreiner
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

5.  Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients.

Authors:  Yong Li; Zhenqing Sun; Kewei Liu; Wensheng Qiu; Ruyong Yao; Tongtong Feng; Chao Xin; Lu Yue
Journal:  Mol Clin Oncol       Date:  2014-07-17

6.  An extensive tumor array analysis supports tumor suppressive role for nucleophosmin in breast cancer.

Authors:  Piia-Riitta Karhemo; Antti Rivinoja; Johan Lundin; Maija Hyvönen; Anastasiya Chernenko; Johanna Lammi; Harri Sihto; Mikael Lundin; Päivi Heikkilä; Heikki Joensuu; Petri Bono; Pirjo Laakkonen
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

7.  Variant Ciz1 is a circulating biomarker for early-stage lung cancer.

Authors:  Gillian Higgins; Katherine M Roper; Irene J Watson; Fiona H Blackhall; William N Rom; Harvey I Pass; Justin F X Ainscough; Dawn Coverley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-16       Impact factor: 11.205

8.  NPM phosphorylation stimulates Cdk1, overrides G2/M checkpoint and increases leukemic blasts in mice.

Authors:  Wei Du; Yun Zhou; Suzette Pike; Qishen Pang
Journal:  Carcinogenesis       Date:  2009-11-23       Impact factor: 4.944

9.  Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.

Authors:  Rebekah Stackpole Zimmerman; Naomi Rosenberg
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

10.  TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice.

Authors:  Yun Zhou; Wei Du; Tara Koretsky; Grover C Bagby; Qishen Pang
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.